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Pruning the regulatory tree
For human-subjects research, maximum regulation does not mean maximum protection. 
Stop regulating minimal risk research, say Scott Kim, Peter Ubel and Raymond De Vries.
The rapid improvement of the US system to protect research subjects is an impor-tant human-rights achievement, but it 
has grown in ways that require careful cultiva-
tion and, at times, cutting back. 
Consider a much-discussed study in which 
Peter Pronovost, a critical-care researcher at 
the Johns Hopkins University in Baltimore, 
Maryland, tested how using a simple check-
list of scientifically proven steps, such as hand 
washing, might reduce catheter-induced 
infections. The study enlisted 108 intensive-
care units in Michigan and over the course of 
18 months it saved an estimated 1,500 lives 
and US$175 million through shorter hospital 
stays. But not long after the results were pub-
lished, the Office for Human 
Research Protections (OHRP) 
at the US Department of 
Health and Human Services 
ordered the hospitals to halt 
data collection on the study. 
Although the OHRP agreed 
that the study was minimal 
risk and did not need informed consent, it 
concluded1 that Johns Hopkins University 
had incorrectly deemed the study exempt from 
review by institutional review boards (IRBs). 
Without this exemption, the study would have 
taken longer, cost more and resulted in greater 
variation between procedures at different 
study sites (given the involvement of dozens of 
IRBs). This is not a case of abuse or even mis-
interpretation of current regulations. Rather, it 
illustrates a serious flaw in the regulations: the 
requirement of extensive and expensive proto-
col reviews that yield no ethical benefit.
Many are frustrated with the current system 
for protecting research subjects: some find it 
too flimsy, others see it as too overbearing2. 
This tension paralyses reform efforts. We pro-
pose a way around the stalemate through a 
simple regulatory change that is far-reaching, 
equitable and yet low risk: exempt minimal-
risk research from IRB review.
Low-risk research protocols are common in 
several disciplines including health-services 
research, education research, history and the 
social sciences.The US Federal regulations 
define minimal-risk research as that in which 
“the probability and magnitude of harm or 
discomfort anticipated in the research are not 
greater in and of themselves than those ordi-
narily encountered in daily life or during the 
performance of routine physical or psychological 
examinations or tests.”3 Review boards routinely 
use the concept in making decisions, but current 
oversight is complex and extensive (see table). 
We propose that institutions streamline 
oversight of minimal-risk research by requir-
ing investigators to complete a brief application 
describing research procedures, risks, burdens 
and the potential loss of otherwise expected 
benefits to the subjects. An institution-
 designated person reviews the application, 
and exempted protocols would not be sub-
ject to further IRB review. The application 
becomes the project’s registration and serves 
as an accountability document. Note that our 
proposal is not meant to apply to minimal-risk 
research involving direct 
interactions with people who 
are incapable of informed 
consent, because research 
with such people raises 
special ethical concerns.
How would our proposal 
affect subject safety? Since 
only those studies with minimal chance of 
minimal harm are exempted, the effect on 
subject welfare would be minimal. What 
about the effect on informed consent and 
subject autonomy? Consider studies that 
require direct interaction with subjects. 
Informal voluntary consent should still be 
given by subjects. This is the prevailing prac-
tice for low-risk interpersonal interactions of 
everyday life in a liberal democratic society, 
and should suffice for minimal-risk research 
interactions too. Indeed, formal consent is 
contrary to the implicit, intuitive norms of 
communication and can even cause mistrust4.
Current regulations justify exceptions to 
formal informed consent mainly by appealing 
to minimal risk. They allow verbal consent 
rather than the usual written consent largely 
based on minimal-risk considerations3. 
Informed consent itself can be waived if the 
study is minimal risk and other conditions 
are met3. We believe that the minimal-risk 
criterion serves as the sole ethical justification 
of these waivers; other regulatory conditions 
(such as the requirement that the research 
would not be ‘practicable’ without the waiver) 
provide no additional ethical justification. 
The burdens of oversight
Although the ethical benefits of regulating 
minimal-risk research are negligible, the costs 
are not. The IRB system is widely recognized 
as being underfunded2 yet a 2005 study5 found 
that 41% of all new protocols reviewed by 
US academic medical centre IRBs are expedited 
(and thus minimal risk). The median annual 
cost for a medical-centre IRB was $750,000. 
Because expedited reviews cost about the same 
as full reviews5, the median cost of expedited 
reviews is approximately $300,000 per year. 
And because 43% of IRBs surveyed do not pay 
their review-board members (who are gener-
ally highly remunerated professionals), these 
costs represent an underestimate of true costs. 
Moreover, minimal-risk-research reviews are 
likely to be more common at non-medical 
centre IRBs. At our institution (a major 
research university with a medical centre), 
“At least half of 
institutional-review-
board costs are devoted 
to evaluating minimal-
risk research.”
EXISTING REVIEW PROCESSES FOR MINIMAL-RISK RESEARCH
Current exemption process3 Current expedited review process3
Researcher submits application — type varies by 
institution.
Researcher submits a full IRB application.
Institution-designated person determines study is 
minimal risk according to de facto standard12.
IRB designee determines whether the study is 
minimal risk.
The protocol must also meet one of six criteria for 
exemption.
The protocol must also meet one of nine criteria for 
expedited review. The IRB designee reviews protocol.
Some IRBs do not allow exemptions, regardless of 
federal criteria.
If informed consent is required, review board and 
investigator will exchange drafts of the consent form.
If waiver/alteration of informed consent, or its 
documentation, is requested, further review is needed.
Changes to the protocol require amendment 
applications to the IRB. Annual review is required.
IRB = institutional review board
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56% of new IRB approvals are expedited, 
with additional 23% that are exempted6. 
Non-medical centre, low-volume IRBs 
(which review a disproportionate number of 
minimal- risk-research protocols) do not enjoy 
economies of scale7. Thus, at least half (and 
probably much more) of all direct IRB costs 
are devoted to expensive reviews of minimal-
risk studies — resources that could be used to 
improve the oversight of riskier studies. 
There are also significant financial and 
scientific costs to researchers and sponsors. Even 
expedited reviews can take several weeks for 
approval, and those few weeks in the brief life of 
a single sponsored project add up to a substan-
tial amount when extrapolated to the thousands 
of such projects. Minor revisions to protocol 
can add weeks of delay and, when pressed for 
time, researchers sometimes accept sub-optimal 
science in order to comply with the rules.
Patients are affected because of lack of 
quality- improvement research. A report8 by 
an interdisciplinary study group notes that the 
current system has “generated disincentives 
to engage in quality improvement” and pro-
duces “inconsistent decisions, increases costs, 
retards improvement, and undermines respect 
for research review”. Quality-improvement 
research has tremendous implications for public 
health. Provonost’s study, for example, addresses 
a problem responsible for 28,000 deaths and 
billions of dollars per year in the United States1. 
There is considerable concern that the OHRP 
actions in this case will have a chilling effect on 
quality-improvement research. 
Unnecessary oversight also generates other 
costs. Some researchers, when asked to conform 
to a system they believe is ethically unnecessary, 
may decide to violate the procedures9. Such 
behaviour can become culturally entrenched 
and passed on from mentor to trainee. We do 
not condone such behaviour, but it is counter-
productive to knowingly support a regulatory 
system that undermines the very intent of those 
regulations. Researchers are also increasingly 
concerned that some types of human-subject 
regulation are a form of censorship and an 
infringement of academic freedom10. 
Institutions have a tendency to impose on 
themselves requirements that are even more 
stringent than those required by law. But a 
new regulation that exempts minimal-risk 
research from IRB review would send a clear 
and unambiguous message that the govern-
ment’s priority is not on intense oversight of 
low-risk research. 
Can minimal-risk research determinations 
be made reliably and validly? Some may point 
to the debates over minimal risk in the paedi-
atric literature as evidence that ‘minimal risk’ 
is a contested concept11. But that literature is 
constrained by the special situation in paediat-
ric research — whether a study is minimal risk 
can determine whether it is allowed at all. The 
situation is very different in our proposal, in 
which a determination of greater than minimal 
risk simply means that a protocol is non-exempt 
and in need of the usual institutional review. 
Who would make the judgement that a 
protocol is minimal risk? The system already 
determines, routinely, which protocols are 
minimal risk. Although no policy is self-inter-
preting, most disagreements that arise will 
be about fuzzy boundaries rather than about 
the large domain of protocols that are clearly 
minimal risk. Such boundary disagreements 
can be conservatively handled without the 
danger of riskier research falling through the 
gaps. Even if the new line were drawn so con-
servatively (which we do not recommend) that 
only 50% of currently expedited protocols were 
made exempt, substantial resources would be 
freed for better uses. There will no doubt be an 
evolution in the interpretation of the concept 
when it is used to exempt rather than expedite 
a protocol review. 
It is unethical to support a system that creates 
a significant financial, scientific, clinical and 
ethical burden with virtually no counterbalanc-
ing good. The maturation of any system involves 
trimming unnecessary parts, and redoubling 
the focus on areas that need further attention. 
Minimal-risk-research oversight should be 
pruned from the federal regulations and made 
exempt. Such pruning is necessary for the long-
term health of the whole by freeing up scarce 
resources to where they are most needed. ■
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